LC
VRTX icon

Lindbrook Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Lindbrook Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$3.06M Buy
6,308
+5,202
+470% +$2.42M 0.28% 53
2024
Q4 		$445K Sell
1,106
-28,526
-96% -$13.2M 0.04% 242
2024
Q3 		$13.8M Buy
29,632
+7,872
+36% +$3.78M 1.22% 13
2024
Q2 		$10.2M Sell
21,760
-8,428
-28% -$3.66M 0.96% 16
2024
Q1 		$12.6M Buy
30,188
+18,996
+170% +$8.03M 1.18% 14
2023
Q4 		$4.55M Buy
11,192
+5,161
+86% +$1.91M 0.45% 42
2023
Q3 		$2.1M Sell
6,031
-5,345
-47% -$1.87M 0.23% 65
2023
Q2 		$4M Sell
11,376
-20,406
-64% -$6.88M 0.43% 42
2023
Q1 		$10M Sell
31,782
-157
-0.5% -$47.1K 1.17% 11
2022
Q4 		$9.22M Buy
31,939
+24,198
+313% +$7.37M 1.14% 12
2022
Q3 		$2.24M Buy
7,741
+3,208
+71% +$923K 0.38% 31
2022
Q2 		$1.28M Buy
4,533
+1,762
+64% +$472K 0.21% 64
2022
Q1 		$723K Buy
2,771
+1,749
+171% +$415K 0.11% 115
2021
Q4 		$224K Buy
1,022
+536
+110% +$104K 0.03% 281
2021
Q3 		$88K Sell
486
-23
-5% -$4.49K 0.02% 292
2021
Q2 		$103K Sell
509
-14
-3% -$2.93K 0.02% 288
2021
Q1 		$112K Buy
523
+11
+2% +$2.42K 0.03% 252
2020
Q4 		$121K Sell
512
-46
-8% -$10.6K 0.03% 209
2020
Q3 		$152K Buy
558
+64
+13% +$17.7K 0.04% 153
2020
Q2 		$143K Sell
494
-8
-2% -$2.17K 0.04% 158
2020
Q1 		$119K Sell
502
-164
-25% -$37.6K 0.05% 166
2019
Q4 		$146K Sell
666
-65
-9% -$13.2K 0.05% 189
2019
Q3 		$124K Sell
731
-15
-2% -$2.65K 0.05% 200
2019
Q2 		$136K Buy
746
+17
+2% +$2.97K 0.05% 184
2019
Q1 		$134K Hold
729
– – 0.05% 182
2018
Q4 		$120K Buy
+729
New +$126K 0.06% 169

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lindbrook Capital's VRTX Position: Q1 2025 in Review

Lindbrook Capital increased its Vertex Pharmaceuticals (VRTX) stake by 470% in Q1 2025, buying an estimated $2.42M and bringing the position to 6,308 shares worth $3.06M. The position accounts for 0.28% of the portfolio, ranked #53.

Lindbrook Capital first reported a position in VRTX in Q4 2018 and has held it in 26 quarters since. The position peaked at $13.8M in Q3 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Lindbrook Capital held 6,308 shares of Vertex Pharmaceuticals worth $3.06M as of Q1 2025.
  • Lindbrook Capital bought 5,202 Vertex Pharmaceuticals shares in Q1 2025, an estimated $2.42M.
  • Vertex Pharmaceuticals made up 0.28% of Lindbrook Capital's portfolio in Q1 2025, its #53 holding.
  • Lindbrook Capital first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Lindbrook Capital's Vertex Pharmaceuticals position peaked at $13.8M in Q3 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.